Artwork

コンテンツは Molecule によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Molecule またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!

Michael Baran on Decentralized Science and Investing in Blockchain Technology

39:45
 
シェア
 

Manage episode 383764675 series 3394247
コンテンツは Molecule によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Molecule またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

Welcome to another episode of the DeSci Podcast. Today, we had the privilege of having Michael Baran as our guest. Michael Baran, MBA, Ph.D. is Executive Director, WRDM, and partner at Pfizer Ventures. In this episode, Michael discusses the unique features of DeSci, highlighting how it is reshaping the scientific landscape and redefining traditional paradigms. We also explored the significant risks in early-stage science investment and discussed key factors deterring investors from entering the cryptocurrency and blockchain sectors. Michael draws insightful comparisons between DeSci and the Traditional model, exploring both their similarities and differences. Other topics we discussed are the underappreciated values of traditional biotech, common misconceptions about Biopharma, the need for maintaining scientific quality, and many more. Feel free to navigate any topics discussed in the Podcast using the timestamps below. ___ ⭐ Timestamps: 0:00 Intro 1:07 What is the strong case for DeSci? 2:57 Advantages of DeSci Over Traditional Biotech 3:00 Risks associated with investing in early-stage science 4:35 DeSci vs. Traditional Model: Similarities and differences 7:38 Strongest critique of Desci 11:09 Measuring success 13:26 Underexplored areas in Biopharma 15:32 Common misconceptions about Biopharma 16:51 Pfizer partnership models 23:40 Underappreciated values of traditional Biotech 26:43 Maintaining scientific quality 28:40 Contentious topics within your field 31:14 Implicit knowledge in Biopharma 34:26 Recurring challenges in Michael's career 35:42 Selecting the best ideas 39:18 Outro ____ If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below. If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to Special thanks to Lea Degen: https://twitter.com/lealeata Michael Baran: https://twitter.com/scienceman2023 ____ Let's connect: Website: https://bit.ly/3d6nh2C X: https://twitter.com/Molecule_dao Discord: https://discord.com/invite/moleculedao

  continue reading

34 つのエピソード

Artwork
iconシェア
 
Manage episode 383764675 series 3394247
コンテンツは Molecule によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Molecule またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

Welcome to another episode of the DeSci Podcast. Today, we had the privilege of having Michael Baran as our guest. Michael Baran, MBA, Ph.D. is Executive Director, WRDM, and partner at Pfizer Ventures. In this episode, Michael discusses the unique features of DeSci, highlighting how it is reshaping the scientific landscape and redefining traditional paradigms. We also explored the significant risks in early-stage science investment and discussed key factors deterring investors from entering the cryptocurrency and blockchain sectors. Michael draws insightful comparisons between DeSci and the Traditional model, exploring both their similarities and differences. Other topics we discussed are the underappreciated values of traditional biotech, common misconceptions about Biopharma, the need for maintaining scientific quality, and many more. Feel free to navigate any topics discussed in the Podcast using the timestamps below. ___ ⭐ Timestamps: 0:00 Intro 1:07 What is the strong case for DeSci? 2:57 Advantages of DeSci Over Traditional Biotech 3:00 Risks associated with investing in early-stage science 4:35 DeSci vs. Traditional Model: Similarities and differences 7:38 Strongest critique of Desci 11:09 Measuring success 13:26 Underexplored areas in Biopharma 15:32 Common misconceptions about Biopharma 16:51 Pfizer partnership models 23:40 Underappreciated values of traditional Biotech 26:43 Maintaining scientific quality 28:40 Contentious topics within your field 31:14 Implicit knowledge in Biopharma 34:26 Recurring challenges in Michael's career 35:42 Selecting the best ideas 39:18 Outro ____ If you prefer listening to podcasts on audio apps, feel free to search for "The DeSci Podcast" on Spotify, Google Podcasts & Apple Podcasts. You'll also find all links to the podcast apps below. If you want to join us on the show as a speaker or have guest ideas, please shoot us an mail at podcast@molecule.to Special thanks to Lea Degen: https://twitter.com/lealeata Michael Baran: https://twitter.com/scienceman2023 ____ Let's connect: Website: https://bit.ly/3d6nh2C X: https://twitter.com/Molecule_dao Discord: https://discord.com/invite/moleculedao

  continue reading

34 つのエピソード

すべてのエピソード

×
 
Loading …

プレーヤーFMへようこそ!

Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。

 

クイックリファレンスガイド